National MS Society Invests in Clinical Development of Human Antibody for Progressive Forms of MS
Fast Forward, a nonprofit subsidiary of theĀ National Multiple Sclerosis Society, will invest up to $330,000 to advance the clinical development of an antibody that was shown to lessen inflammation and nerve cell damage in a multiple sclerosisĀ (MS) mouse model. The funding will help develop the antibody (aĀ protein…